论文部分内容阅读
目的:探讨乳腺癌患者新辅助化疗前后血清CA15-3、CA125和CEA水平的变化。方法:应用化学发光免疫分析法(CLIA)检测60例乳腺癌(Ⅰ期30例,II-IV期各10例)患者新辅助化疗前后血清CA15-3、CA125和CEA表达水平,并与60例非肿瘤患者作比较。结果:乳腺癌患者化疗前血清CA15-3、CA125和CEA含量显著高于非肿瘤患者组(P<0.01);三者联合检测较单一检测阳性率明显增高。Ⅰ+Ⅱ期患者行新辅助化疗3个疗程后CA15-3、CA125和CEA水平显著下降(P<0.05),与非肿瘤患者组比较无统计学差异;Ⅲ+Ⅳ期患者行新辅助化疗3个疗程后CA15-3、CA125和CEA水平明显下降(P<0.05),但仍高于非肿瘤患者组(P<0.05).结论:血清免疫指标CA15-3、CA125、CEA变化对临床诊断和预后观察具有重要的临床价值。
Objective: To investigate the changes of serum CA15-3, CA125 and CEA in patients with breast cancer before and after neoadjuvant chemotherapy. Methods: The expressions of CA15-3, CA125 and CEA in 60 cases of breast cancer (30 in stage Ⅰ and 10 in stage II-IV) after neoadjuvant chemotherapy were detected by chemiluminescence immunoassay (CLIA), and were compared with 60 Non-tumor patients for comparison. Results: The levels of serum CA15-3, CA125 and CEA in patients with breast cancer before chemotherapy were significantly higher than those in non-cancer patients (P <0.01). The positive rates of the three tests were significantly higher than those of single tests. The levels of CA15-3, CA125 and CEA in patients with stage Ⅰ + Ⅱ were significantly decreased after 3 courses of neoadjuvant chemotherapy (P <0.05), and there was no significant difference between the patients with stage Ⅲ + Ⅳ and neoadjuvant chemotherapy 3 The levels of CA15-3, CA125 and CEA after treatment were significantly decreased (P <0.05), but still higher than those in non-tumor patients (P <0.05) .Conclusion: Serum immune parameters CA15-3, CA125 and CEA changes in clinical diagnosis and Prognosis has important clinical value.